When biosimilars first hit the market, the expectation was straightforward: they'd be cheaper, brand-name would be pricier, and patients would gradually shift to the lower-cost versions. The reality turned out to be much stranger.
In 2023–2024, brand-name Humira's net price actually dropped below the net price of some of its biosimilars. For patients and prescribers trying to figure out which version is most affordable, this created a genuinely confusing situation.
Here's what happened, why it matters, and what you should actually do with this information.
How Did Humira End Up Cheaper Than Some Biosimilars?
The answer is rebates.
Pharmaceutical pricing isn't as simple as the sticker price at the pharmacy. What insurers and pharmacy benefit managers (PBMs) actually pay — the "net price" — is the list price minus confidential rebates that manufacturers pay to secure formulary placement.
AbbVie, in response to biosimilar competition, offered large rebates to PBMs to keep Humira on preferred formulary tiers. This drove Humira's net price down. Meanwhile, some biosimilar manufacturers priced their products at a discount to Humira's list price, but didn't match the depth of rebates AbbVie was offering.
The result: by late 2023, Humira's net price to payers in some contracts was approximately $2,798 per month, while certain biosimilars were running $3,452–$4,793 per month in net price terms — because the biosimilar manufacturers weren't offering the same size of rebates.
What This Looks Like From a Patient's Perspective
This is where the price inversion becomes confusing in practice.
For patients paying out of pocket or with high-deductible plans, what matters is the cash price or the pre-deductible cost — not the net price. At the pharmacy counter, brand Humira can still cost significantly more than its biosimilars if you're paying list price or a percentage of list price.
For insured patients, what matters is which tier your drug is on and what your plan's copay structure looks like. If your PBM has struck a better rebate deal with AbbVie than with the biosimilar manufacturers, Humira might be on a preferred tier with a lower copay — even though that seems backwards.
For insurance companies and PBMs, the net price is what they optimize around. The rebate-driven inversion creates a situation where plans can legitimately argue that covering brand Humira is less expensive than covering some biosimilars — which is why some formularies have kept Humira on preferred status even after biosimilars launched.
The Three-Tier Adalimumab Pricing Reality
As of 2026, the adalimumab market has effectively split into three pricing segments:
High-concentration biosimilars (citrate-free): Hyrimoz HD, Yuflyma, and others. These reformulations match the newer Humira formulation (citrate-free, which causes less injection-site pain) and are often preferred in clinical settings. They tend to be priced at a premium among biosimilars.
Standard biosimilars: Amjevita, Hadlima, Cyltezo, and others at the original concentration. Generally the lowest-priced segment, with significant competition keeping prices down.
Brand Humira with rebates: In some formularies, effectively priced competitively with high-concentration biosimilars due to AbbVie's rebate strategy.
What Should You Actually Do With This Information?
A few practical takeaways:
Don't assume the biosimilar is cheaper for you. Ask your pharmacist for the cash price on both brand Humira and the specific biosimilar your doctor wants to prescribe. The answer may surprise you.
Check your formulary tier. Log in to your insurance portal and search for both "adalimumab" and "Humira." Compare the copay tier. Sometimes brand Humira is on a lower tier than biosimilars with your specific plan.
If you're uninsured, the price inversion at the list price level matters. Check GoodRx for both brand and biosimilar options. Cyltezo in particular has a GoodRx partnership that can reduce uninsured costs significantly.
If cost is the primary concern, patient assistance programs — for both Humira and biosimilars — are likely to produce better outcomes than comparing cash prices. See our guide to which PAP to use based on your situation.
This article discusses pricing dynamics based on publicly available data and reporting. Net prices are subject to confidential rebate agreements and vary by plan. Always verify current pricing with your pharmacy or insurer.